Impact of the Inflammatory Burden Index on Prognosis After Hepatectomy for Colorectal Liver Metastasis.

IF 1 4区医学 Q3 SURGERY American Surgeon Pub Date : 2025-01-09 DOI:10.1177/00031348251313993

Hironari Kawai, Kenei Furukawa, Masashi Tsunematsu, Yoshihiro Shirai, Shinji Onda, Koichiro Haruki, Michinori Matsumoto, Norimitsu Okui, Tomohiko Taniai, Toru Ikegami

{"title":"Impact of the Inflammatory Burden Index on Prognosis After Hepatectomy for Colorectal Liver Metastasis.","authors":"Hironari Kawai, Kenei Furukawa, Masashi Tsunematsu, Yoshihiro Shirai, Shinji Onda, Koichiro Haruki, Michinori Matsumoto, Norimitsu Okui, Tomohiko Taniai, Toru Ikegami","doi":"10.1177/00031348251313993","DOIUrl":null,"url":null,"abstract":"Background/aim: The aim of this study was to investigate the prognostic impact of the inflammatory burden index (IBI), a novel inflammation-based biomarker, in patients with colorectal liver metastases (CRLM) after hepatic resection.Patients and methods: One hundred fifty patients with CRLM who underwent hepatectomy were retrospectively analyzed. The IBI was defined as C-reactive protein × neutrophil count/lymphocyte count. The relationship of the IBI with overall survival was investigated by univariate and multivariate analyses.Results: Seventy-three (49%) patients had a high IBI (>3.45). In univariate analysis, overall survival was significantly worse in patients with lymph node metastases (P = 0.048), high NLR (P = 0.03), and high IBI (P < 0.01). In multivariate analysis, high IBI (P = 0.048) was an independent and significant predictor of overall survival. Patients with a high IBI had more postoperative complications compared with those with a low IBI (P < 0.01).Conclusion: The IBI was a strong predictor for both short- and long-term outcomes in patients who underwent hepatic resection for CRLM.","PeriodicalId":7782,"journal":{"name":"American Surgeon","volume":" ","pages":"31348251313993"},"PeriodicalIF":1.0000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Surgeon","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00031348251313993","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: The aim of this study was to investigate the prognostic impact of the inflammatory burden index (IBI), a novel inflammation-based biomarker, in patients with colorectal liver metastases (CRLM) after hepatic resection.

Patients and methods: One hundred fifty patients with CRLM who underwent hepatectomy were retrospectively analyzed. The IBI was defined as C-reactive protein × neutrophil count/lymphocyte count. The relationship of the IBI with overall survival was investigated by univariate and multivariate analyses.

Results: Seventy-three (49%) patients had a high IBI (>3.45). In univariate analysis, overall survival was significantly worse in patients with lymph node metastases (P = 0.048), high NLR (P = 0.03), and high IBI (P < 0.01). In multivariate analysis, high IBI (P = 0.048) was an independent and significant predictor of overall survival. Patients with a high IBI had more postoperative complications compared with those with a low IBI (P < 0.01).

Conclusion: The IBI was a strong predictor for both short- and long-term outcomes in patients who underwent hepatic resection for CRLM.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

American Surgeon 医学-外科

CiteScore

1.40

自引率

0.00%

发文量

623

期刊介绍： The American Surgeon is a monthly peer-reviewed publication published by the Southeastern Surgical Congress. Its area of concentration is clinical general surgery, as defined by the content areas of the American Board of Surgery: alimentary tract (including bariatric surgery), abdomen and its contents, breast, skin and soft tissue, endocrine system, solid organ transplantation, pediatric surgery, surgical critical care, surgical oncology (including head and neck surgery), trauma and emergency surgery, and vascular surgery.